272 related articles for article (PubMed ID: 30797084)
1. Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections.
Rappo U; Gonzalez PL; Puttagunta S; Akinapelli K; Keyloun K; Gillard P; Liu Y; Dunne MW
J Glob Antimicrob Resist; 2019 Jun; 17():60-65. PubMed ID: 30797084
[TBL] [Abstract][Full Text] [Related]
2. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.
Turco NJ; Kane-Gill SL; Hernandez I; Oleksiuk LM; D'Amico F; Pickering AJ
Expert Opin Pharmacother; 2018 Mar; 19(4):319-325. PubMed ID: 29509504
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study).
Bai F; Aldieri C; Cattelan A; Raumer F; Di Meco E; Moioli MC; Tordato F; Morelli P; Borghi F; Rizzi M; Van Hauwermeiren E; Castelli F; Migliorino G; Menzaghi B; Rizzardini G; Saracino A; Cascio A; Puoti M; d'Arminio Monforte A; Marchetti G
Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1271-1279. PubMed ID: 32797758
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.
Dunne MW; Puttagunta S; Giordano P; Krievins D; Zelasky M; Baldassarre J
Clin Infect Dis; 2016 Mar; 62(5):545-51. PubMed ID: 26611777
[TBL] [Abstract][Full Text] [Related]
5. Current trends in the real-life use of dalbavancin: report of a study panel.
Durante-Mangoni E; Gambardella M; Iula VD; De Stefano GF; Corrado MF; Esposito V; Gentile I; Coppola N
Int J Antimicrob Agents; 2020 Oct; 56(4):106107. PubMed ID: 32721599
[TBL] [Abstract][Full Text] [Related]
6. The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).
Soriano A; Rossolini GM; Pea F
Expert Rev Anti Infect Ther; 2020 May; 18(5):415-422. PubMed ID: 32223465
[No Abstract] [Full Text] [Related]
7. Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.
Scott LJ
Drugs; 2015 Jul; 75(11):1281-91. PubMed ID: 26105117
[TBL] [Abstract][Full Text] [Related]
8. Once-weekly dalbavancin versus daily conventional therapy for skin infection.
Boucher HW; Wilcox M; Talbot GH; Puttagunta S; Das AF; Dunne MW
N Engl J Med; 2014 Jun; 370(23):2169-79. PubMed ID: 24897082
[TBL] [Abstract][Full Text] [Related]
9. REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI.
Papavramidis T; Gentile I; Cattelan AM; Magnasco L; Viale P; Francisci D; Kofteridis DP; Tiseo G; Giamarellos-Bourboulis EJ; Lagi F; Pinna SM; D'Amico F; La Ferla L; Panagopoulos P; Gattuso G; Sipsas NV; Ruggieri A; Cattaneo A; Corio L; Comandini A; Mascagni P; Bassetti M
Int J Antimicrob Agents; 2023 Apr; 61(4):106746. PubMed ID: 36758778
[TBL] [Abstract][Full Text] [Related]
10. Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries.
Marcellusi A; Bini C; Andreoni M; Sarmati L; Espin J; Horcajada JP; Czypionka T; Andretta D; Sciattella P; Favato G; Mennini FS
Clin Drug Investig; 2020 Apr; 40(4):305-318. PubMed ID: 32034687
[TBL] [Abstract][Full Text] [Related]
11. New antibiotics in the management of acute bacterial skin and skin structure infections.
Gleghorn K; Grimshaw E; Kelly EK
Skin Therapy Lett; 2015; 20(5):7-9. PubMed ID: 26382907
[TBL] [Abstract][Full Text] [Related]
12. A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections.
Dunne MW; Zhou M; Darpo B
Int J Antimicrob Agents; 2015 Apr; 45(4):393-8. PubMed ID: 25681068
[TBL] [Abstract][Full Text] [Related]
13. Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.
Garnock-Jones KP
Drugs; 2017 Jan; 77(1):75-83. PubMed ID: 27988870
[TBL] [Abstract][Full Text] [Related]
14. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
Jauregui LE; Babazadeh S; Seltzer E; Goldberg L; Krievins D; Frederick M; Krause D; Satilovs I; Endzinas Z; Breaux J; O'Riordan W
Clin Infect Dis; 2005 Nov; 41(10):1407-15. PubMed ID: 16231250
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections.
Galluzzo M; D'Adamio S; Bianchi L; Talamonti M
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):197-206. PubMed ID: 29258361
[TBL] [Abstract][Full Text] [Related]
16. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W;
Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250
[TBL] [Abstract][Full Text] [Related]
17. Acute bacterial skin and skin structure infections in pediatric patients: potential role of dalbavancin.
Volpicelli L; Venditti M; Oliva A
Expert Rev Anti Infect Ther; 2023 Apr; 21(4):329-341. PubMed ID: 36803139
[TBL] [Abstract][Full Text] [Related]
18. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
Wunsch S; Krause R; Valentin T; Prattes J; Janata O; Lenger A; Bellmann-Weiler R; Weiss G; Zollner-Schwetz I
Int J Infect Dis; 2019 Apr; 81():210-214. PubMed ID: 30794940
[TBL] [Abstract][Full Text] [Related]
19. The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives.
Andreoni M; Bassetti M; Corrao S; De Rosa FG; Esposito V; Falcone M; Grossi P; Pea F; Petrosillo N; Tascini C; Venditti M; Viale P
Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1125-1134. PubMed ID: 33682593
[TBL] [Abstract][Full Text] [Related]
20. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
Ramdeen S; Boucher HW
Expert Opin Pharmacother; 2015; 16(13):2073-81. PubMed ID: 26239321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]